Moon Tree at New Mexico museum soon to be unveiled to public
LAS CRUCES, N.M. (KRQE) – Walking through the New Mexico Farm and Ranch Heritage Museum in Las Cruces, you might walk by a particular pine tree without a second glance. But, it has a story that's truly out of this world. 'They were seeds that were on the Artemis one mission,' said Paul Steward, Instructional Coordinator at New Mexico Farm and Ranch Heritage Museum.
Story continues below
News: Governor Michelle Lujan Grisham authorizes National Guard deployment to Albuquerque
Trending: NMSU: 6 international students' visas revoked by federal government
News: Suspect in custody after fleeing from police in a U-Haul with people in the back
Education: Curanderismo in the classroom: Albuquerque high school teacher introduces students to Mexican folk healing
That's right, it is a Moon Tree. The pine tree growing in the museum's garden started as one of the hundreds of seeds that went on NASA's Artemis I mission in 2022, where they orbited the moon. It was a nod to the first moon tree project aboard Apollo 14. The New Mexico Farm and Ranch Heritage Museum was just one of the places across the country to receive one of these moon trees last year. 'I was very happy when we found out that we were going to get one of the moon trees,' said Steward. 'We got it in the ground right away. And we planted it in there, gave it some fertilizer.'
He said in the last year, they haven't noticed any impact the seed's time in space may have had on the tree. 'It's been doing ok. It has a little bit of brown on some of its pine needles, so we've added some more soil to it, some more nutrients,' said Steward. 'I think it's getting greener and doing a little bit better.'
And now, it's ready to be seen by museum-goers. The Moon Tree will be unveiled to the public on April 11 from 10:30 a.m. to 12:30 p.m. in the under-construction outdoor classroom (formerly known as the Discovery Garden) at NMFRHM. The museum hopes the tree that launched into space will help launch new interest about science, plants, and space exploration.
'That it sparks that excitement for them, the curiosity to learn more about what's going on with growing plants in space,' said Steward.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Japan's ispace tries lunar touchdown again with Resilience lander
By Kantaro Komiya TOKYO (Reuters) -Japanese company ispace is set to try the lunar touchdown of its uncrewed spacecraft again on Friday two years after its failed inaugural mission, in a bid to become the first company outside the United States to achieve a moon landing. Tokyo-based ispace hopes to join U.S. firms Intuitive Machines and Firefly Aerospace, which have accomplished commercial landings amid an intensifying global race for the moon that includes state-run missions from China and India. Resilience, ispace's second lunar lander, is expected to touch down on Mare Frigoris, a basaltic plain about 900 km (560 miles) from the moon's north pole, at 4:17 a.m. Friday local time (1917 GMT Thursday) following an hour-long descent from lunar orbit, according to the company. In 2023, ispace's first lander crashed into the moon's surface due to inaccurate recognition of its altitude. Software remedies have been implemented, while the hardware design is mostly unchanged in Resilience, the company has said. Resilience carries a four-wheeled rover built by ispace's Luxembourg subsidiary and payloads worth a total of $16 million, including scientific instruments from Japanese firms and a Taiwanese university. If the landing is successful, the 2.3-metre-high lander and the microwave-sized rover will begin 14-day exploration activities until the arrival of a freezing-cold lunar night, including capturing images of regolith, the moon's fine-grained surface material, on a contract with U.S. space agency NASA. Later on Friday, ispace will host a press conference about the outcome of the mission, according to the company. Shares in ispace more than doubled earlier this year on growing investor hopes for the second mission, before calming in recent days. Resilience in January shared a SpaceX rocket launch with Firefly's Blue Ghost lander, which took a faster trajectory to the moon and touched down successfully in March. Intuitive Machines, which last year marked the world's first touchdown of a commercial lunar lander, made its second attempt in March but the lander Athena ended on its side on the lunar surface just as in the first mission. Japan last year became the world's fifth country to achieve a soft lunar landing after the former Soviet Union, the U.S., China and India, when the national Japan Aerospace Exploration Agency (JAXA) achieved the touchdown of its SLIM lander, yet also in a toppled position. Despite President Donald Trump's proposed changes to the U.S. space policy, Japan remains committed to NASA's Artemis moon program, pledging the involvement of Japanese astronauts and technologies for future lunar missions. Including one in 2027 as part of the Artemis program, ispace plans seven more missions in the U.S. and Japan through 2029 to capture increasing demands for lunar transportation.
Yahoo
4 hours ago
- Yahoo
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study for EB103. EB103 is an innovative CD19-redirected ARTEMIS T-cell therapy designed to treat advanced B-cell Non-Hodgkin's Lymphomas (NHL). This next phase follows a successful first cohort, which reported no dose-limiting toxicities or serious adverse events, and even saw a complete response in one patient. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. The second cohort will test EB103 at a higher dose, aiming to further establish safety and efficacy. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s CEO, Cheng Liu, highlighted the therapy's potential to overcome limitations of conventional CAR-T treatments, particularly for high-risk groups such as patients with HIV-associated or CNS lymphomas, populations often excluded from current therapies. EB103 leverages proprietary ARTEMIS technology, allowing T-cells to more precisely target and destroy cancer cells. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s pipeline also includes EB104, targeting both CD19 and CD22 proteins found in most B-cell malignancies. The company's progress signals hope for broader, safer, and more effective immunotherapies for cancer and autoimmune disease patients. While we acknowledge the potential of ESLA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ESLA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Business Wire
6 hours ago
- Business Wire
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ('Estrella' or the 'Company'), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, is now open for patient enrollment. 'Partnering with Baylor Research Institute, a nationally recognized medical institution, represents a key step forward in broadening the reach of our STARLIGHT-1 trial,' said Cheng Liu, Chief Executive Officer of Estrella. 'The expansion of our clinical footprint will help accelerate development and increase patient access to EB103, while we remain focused on our mission to deliver safer, more effective treatments for patients with advanced NHL.' The Phase I/II clinical trial for EB103 is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of EB103 autologous T-cell therapy and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study includes a dose escalation phase followed by an expansion phase. Further details of the trial can be found at under NCT identifier: NCT06343311. About EB103 EB103, a T-cell therapy, also referred to as Estrella's 'CD19-Redirected ARTEMIS ® T-Cell Therapy,' utilizes ARTEMIS ® technology licensed from Eureka Therapeutics, Inc. ('Eureka'), Estrella's parent company. Unlike a traditional CAR-T cell, the unique design of an ARTEMIS ® T-Cell, like EB103 T-cell, allows it to be activated and regulated upon engagement with cancer targets that use a cellular mechanism more closely resembling the one from an endogenous T-cell receptor. Once infused, EB103 T-cells seek out CD19-positive cancer cells, bind to these cells, and destroy them. About Estrella Immunopharma Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancers and autoimmune diseases. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella's lead product candidate, EB103, utilizes Eureka's ARTEMIS ® technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka's ARTEMIS ® technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. For more information about Estrella, please visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including but not limited to those regarding the potential benefits and therapeutic advantages of EB103 and ARTEMIS ® T-cell therapy, the anticipated progress and milestones of the STARLIGHT-1 Phase I/II clinical trial, and the future development plans for EB103, are based on our management's current expectations, estimates, forecasts, and projections about the industry and markets in which we operate and our management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors that could cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under 'Risk Factors' and elsewhere in our filings with the Securities and Exchange Commission. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
